Best Practices

Is Your Practice Biosimilar Ready?

Publish date: May 9, 2017
This article was funded and directed by Janssen Biotech, Inc. The editors and staff of Rheumatology News were not involved in the writing or review of this supplement.

 

Click Here to Read the Full Supplement.

Topics include:

  • The Pathway for Biosimilar Approval
  • The Difference between Biosimilars and Generics
  • Draft Interchangeablity Guidelines
  • ACR Position Statement on Biosimilars
  • Effect of the Reimbursement Model on Biosimilars

Click Here to Read the Full Supplement.

Recommended Reading

The EHR Report: Communication, social media, and legal vulnerability
MDedge Rheumatology
EHR price alert doesn’t reduce lab orders
MDedge Rheumatology
VIDEO: Geeks brave rain to March for Science
MDedge Rheumatology
Science advocates take to D.C. streets in March for Science
MDedge Rheumatology
Drugmakers Dramatically Boosted Lobbying Spending In Trump’s First Quarter
MDedge Rheumatology
GOP health reform: Essential health benefits, community rating under fire
MDedge Rheumatology
HHS Secretary Price promises reduced health IT burden for physicians
MDedge Rheumatology
Executive order aims to reform specialized visa program
MDedge Rheumatology
House barely passes ACA repeal/replace bill
MDedge Rheumatology
Restoring the promise of (really) meaningful use
MDedge Rheumatology